Boundless Bio, Inc. (BOLD)

Boundless Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-61.76	-65.36	-49.43	-45.9	-25.21
Depreciation & Amortization	1.24	1.09	0.96	0.94	0.68
Stock-Based Compensation	6.8	7.52	3.34	2.29	1.16
Other Adjustments	2.13	-4.55	-3.46	0.95	0.5
Changes in Accounts Payable	-1.39	0.78	1.66	1.91	1.22
Changes in Other Operating Activities	0.76	-0.3	0.09	0.22	-1.6
Operating Cash Flow	-52.12	-60.84	-46.86	-39.6	-23.25
Capital Expenditures	-0.59	-2.54	-0.63	-1.07	-2.03
Purchases of Investments	-183.23	-208.47	-160.12	-42.6	-77.49
Proceeds from Sale of Investments	210.47	184.9	122.5	59.8	20.24
Investing Cash Flow	26.65	-26.1	-38.26	16.13	-59.29
Issuance of Common Stock	0.23	93.17	0.18	0.13	0.21
Net Common Stock Issued (Repurchased)	0.23	93.17	0.18	0.13	0.21
Issuance of Preferred Stock	-	-	99.67	-	105.32
Net Preferred Stock Issued (Repurchased)	-	-	99.67	-	105.32
Other Financing Activities	-0.01	-3.35	-1.96	-	-
Financing Cash Flow	0.23	89.82	97.9	0.13	105.53
Net Cash Flow	-25.23	2.88	12.78	-23.34	22.99
Free Cash Flow	-52.71	-63.38	-47.49	-40.66	-25.28
Free Cash Flow Per Share	-2.36	-3.73	-39.05	-37.03	-29.38
Levered Free Cash Flow	-61.74	-66.34	-47.36	-43.9	-26.94
Unlevered Free Cash Flow	-67.81	-74.24	-52.72	-44.47	-27.03

Updated Nov 5, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q